Altamira Therapeutics Ltd
CYTO
CYTO was delisted on the 19th of December, 2024.
15 hedge funds and large institutions have $1.34M invested in Altamira Therapeutics Ltd in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 2 closing their positions.
650% more call options, than puts
Call options by funds: $45K | Put options by funds: $6K
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
36% more funds holding
Funds holding: 11 → 15 (+4)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
24% less capital invested
Capital invested by funds: $1.77M → $1.34M (-$427K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$201K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$162K |
| 3 |
BFM
Boothbay Fund Management
New York
|
+$114K |
| 4 |
BlackRock
New York
|
+$91.3K |
| 5 |
Two Sigma Investments
New York
|
+$45.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Group One Trading
Chicago,
Illinois
|
-$51.8K |
| 2 |
Simplex Trading
Chicago,
Illinois
|
-$47K |
| 3 |
Squarepoint
New York
|
-$36K |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$14.6K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$12.4K |
CYTO Hedge Fund Activity: Q3 2021 in Review
15 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Altamira Therapeutics Ltd (CYTO) for Q3 2021, worth a combined $1.34M — down 24% from $1.77M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new CYTO positions and 2 closed out — a net gain of 4 holders — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $201K. The largest seller was Group One Trading, cutting an estimated $51.8K.
- 15 institutional investors held Altamira Therapeutics Ltd (CYTO) as of Q3 2021, up from 11 in Q2 2021.
- Funds reported $1.34M of Altamira Therapeutics Ltd stock for Q3 2021, down 24% quarter-over-quarter.
- 6 funds opened new Altamira Therapeutics Ltd positions in Q3 2021 and 2 closed out, a net change of +4 holders.
- The largest Altamira Therapeutics Ltd buyer in Q3 2021 was Renaissance Technologies, an estimated $201K added.
- The largest Altamira Therapeutics Ltd seller in Q3 2021 was Group One Trading, an estimated $51.8K sold.
Based on aggregated 13F filings for Q3 2021.